New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 18, 2013
07:21 EDTJAZZJazz Pharmaceuticals price target raised to $87 from $76 at Lazard Capital
Lazard Capital raised its price target fort Jazz Pharmaceuticals citing expectations for robust Xyrem revenue growth and keeps a Buy rating on the stock.
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
09:57 EDTJAZZJazz Pharmaceuticals management to meet with JPMorgan
Subscribe for More Information
February 25, 2015
10:47 EDTJAZZJazz Pharmaceuticals participates in a conference call with BMO Capital
BMO Capital's Specialty Pharma Analyst Maris hosts a conference call with Jazz's CEO, Bruce Cozadd, on February 25 at 2:30 pm.
07:31 EDTJAZZJazz Pharmaceuticals pullback a buying opportunity, says JPMorgan
JPMorgan says Jazz Pharmaceuticals' weaker than expected 2015 earnings outlook was not driven by any softness in the company's core driver, Xyrem, but rather non-operating/one-off issues. The firm recommends using the share sell-off as a buying opportunity and keeps an Overweight rating on Jazz with a $190 price target.
February 24, 2015
16:18 EDTJAZZJazz Pharmaceuticals announces retirement of CMO
Subscribe for More Information
16:17 EDTJAZZJazz Pharmaceuticals sees 2015 EPS $9.45-$9.75, consensus $10.11
Subscribe for More Information
16:16 EDTJAZZJazz Pharmaceuticals reports Q4 EPS $2.44, consensus $2.30
Subscribe for More Information
15:21 EDTJAZZNotable companies reporting after market close
Subscribe for More Information
February 20, 2015
13:38 EDTJAZZLeerink specialty pharma analyst holds analyst/industry conference call
Subscribe for More Information
10:01 EDTJAZZOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Advanced Drainage (WMS) initiated with an Outperform at Boenning & Scattergood... Arctic Cat (ACAT) initiated with a Hold at BB&T... Ardmore Shipping (ASC) initiated with an Accumulate at Global Hunter... Baltic Trading (BALT) initiated with a Speculative Buy at Global Hunter... Cash America (CSH) initiated with a Buy at Jefferies... Costamare (CMRE) initiated with an Accumulate at Global Hunter... DHT Holdings (DHT) initiated with a Buy at Global Hunter... Danaos (DAC) initiated with a Neutral at Global Hunter... Diana Containerships (DCIX) initiated with a Neutral at Global Hunter... Diana Shipping (DSX) initiated with a Neutral at Global Hunter... Euronav NV (EURN) initiated with a Buy at Global Hunter... Forest City (FCE.A) initiated with a Neutral at Citigroup... Fox Factory (FOXF) initiated with a Hold at BB&T... Frontline (FRO) initiated with an Accumulate at Global Hunter... Global Ship Lease (GSL) initiated with a Neutral at Global Hunter... GrubHub (GRUB) initiated with an Overweight at Barclays... Jazz Pharmaceuticals (JAZZ) initiated with an Outperform at BMO Capital... Kinder Morgan (KMI) reinstated with an Overweight at Barclays... Liberty Broadband (LBRDA) initiated with an Outperform at FBN Securities... Liberty Interactive (QVCA) initiated with a Sector Perform at FBN Securities... Liberty Media (LMCA) initiated with an Outperform at FBN Securities... MEI Pharma (MEIP) initiated with a Buy at BofA/Merrill... Navios Acquisition (NNA) initiated with a Buy at Global Hunter... Polaris Industries (PII) initiated with a Buy at BB&T... Raven (RAVN) initiated with an Equal Weight at Stephens... Scorpio Bulkers (SALT) initiated with a Speculative Buy at Global Hunter... Scorpio Tankers (STNG) initiated with an Accumulate at Global Hunter... Seaspan (SSW) initiated with a Neutral at Global Hunter... Star Bulk Carriers (SBLK) initiated with a Speculative Buy at Global Hunter... Tsakos Energy (TNP) initiated with a Buy at Global Hunter... U.S. Concrete (USCR) initiated with an Overweight at Stephens.
05:40 EDTJAZZJazz Pharmaceuticals initiated with an Outperform at BMO Capital
Subscribe for More Information
February 12, 2015
08:37 EDTJAZZJazz Pharmaceuticals to present data on defibrotide for hepatic VOD
Jazz Pharmaceuticals announced that researchers will present data on the use of defibrotide, an investigational medicine being studied in the U.S. for the treatment of hepatic veno-occlusive disease or VOD, a rare, potentially life-threatening, early complication in patients undergoing hematopoietic stem-cell transplantation therapy. The three presentations include an update from an ongoing treatment investigational new drug study in the U.S., as well as updates from a number needed to treat analysis from a historically controlled pivotal Phase 3 trial in patients undergoing HSCT therapy, and from an international defibrotide compassionate use program. In 2014, Jazz Pharmaceuticals acquired the rights to defibrotide in the U.S. and other markets in North America, South America and Central America. Defibrotide has a Fast Track regulatory path designation in the U.S. for the treatment of severe VOD. The company has initiated a rolling new drug application submission to the FDA for defibrotide for the treatment of severe VOD and anticipates completing the submission in 1H15.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use